HROW News and Press, Harrow Health Inc. From 05/13/24

Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow’s rapidly growing p...

2024-05-12 17:35:55 ET Major earnings expected after the bell on Monday include: Petróleo Brasileiro S.A. - Petrobras ( PBR ) Lithium Americas (Argentina) Corp. ( LAC ) StoneCo Ltd. ( STNE ) Inovio Pharmaceuticals ( INO ) Alcon ( ALC ) ...

2024-05-12 17:35:00 ET More on Harrow Health Harrow: Merits A Buy On Sales Potential Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom Harrow, Inc. (HROW) Q4 2023 Earnings Call Transcript Harrow Health Q4 2023 Earnings Preview Seekin...

2024-05-02 12:20:24 ET Summary Harrow, Inc. shares have dropped 45% since spring 2023, but the launch of Iheezo and Vevye suggest a potential rebound. Iheezo, an ocular anesthetic, has a substantial market opportunity and is expected to drive significant revenue for Harrow. Ve...

2024-05-02 04:42:01 ET Summary Harrow's long-term bull thesis is stronger than ever, but there may be a credible short-term bear thesis. The short-term bear thesis is the result of the Change Healthcare cyberattack, which has crippled reimbursement and caused huge financial headac...

2024-05-01 22:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on May 14, 2024 Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after ...

2024-04-12 17:05:37 ET Gainers: Applied Optoelectronics ( AAOI ) +5% . Eliem Therapeutics ( ELYM ) +4% . Infinera Corporation ( INFN ) +4% . Harrow ( HROW ) +4% . Health Catalyst ( HCAT ) +4% . Losers: Eagle Pharmaceutica...

MELT-300 Pivotal Phase 3 Program Topline Readout Expected in Q4 2024 Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B Preferred Stock fina...